{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Moderate+to+Severe+Dry+Eye+Disease",
    "query": {
      "condition": "Moderate to Severe Dry Eye Disease"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 25,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Moderate+to+Severe+Dry+Eye+Disease&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-26T11:22:01.605Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00128245",
      "title": "Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Keratoconjunctivitis Sicca"
      ],
      "interventions": [
        {
          "name": "Pimecrolimus",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 440,
      "start_date": "2004-09",
      "completion_date": "2006-12",
      "has_results": false,
      "last_update_posted_date": "2020-05-27",
      "last_synced_at": "2026-06-26T11:22:01.605Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00128245"
    },
    {
      "nct_id": "NCT04096898",
      "title": "Senofilcon A Lenses in Moderate to Severe Dry Eye Disease",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Moderate to Severe Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "Senofilcon A contact lens",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Illinois at Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2018-04-23",
      "completion_date": "2020-12-31",
      "has_results": false,
      "last_update_posted_date": "2020-03-24",
      "last_synced_at": "2026-06-26T11:22:01.605Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04096898"
    },
    {
      "nct_id": "NCT02843659",
      "title": "Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sjögren's Syndrome"
      ],
      "interventions": [
        {
          "name": "BMS-931699",
          "type": "DRUG"
        },
        {
          "name": "BMS-986142",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 45,
      "start_date": "2016-10-18",
      "completion_date": "2017-07-24",
      "has_results": true,
      "last_update_posted_date": "2018-10-04",
      "last_synced_at": "2026-06-26T11:22:01.605Z",
      "location_count": 17,
      "location_summary": "Fullerton, California • Palo Alto, California • Sarasota, Florida + 14 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Lawrenceville",
          "state": "Georgia"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02843659"
    },
    {
      "nct_id": "NCT07041099",
      "title": "A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sjögren",
        "Sjogren Disease",
        "Sjogren's Syndrome"
      ],
      "interventions": [
        {
          "name": "CLN-978",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cullinan Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2025-10-01",
      "completion_date": "2029-03-15",
      "has_results": false,
      "last_update_posted_date": "2026-03-23",
      "last_synced_at": "2026-06-26T11:22:01.605Z",
      "location_count": 5,
      "location_summary": "Orlando, Florida • Memphis, Tennessee • Plano, Texas + 2 more",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Plano",
          "state": "Texas"
        },
        {
          "city": "Webster",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07041099"
    },
    {
      "nct_id": "NCT06947850",
      "title": "DOMPE -MT Neurotrophic Keratitis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dry Eye",
        "Neurotrophic Keratitis"
      ],
      "interventions": [
        {
          "name": "Cenegermin Ophthalmic Solution [Oxervate]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Toyos Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 10,
      "start_date": "2023-01-21",
      "completion_date": "2025-09-25",
      "has_results": false,
      "last_update_posted_date": "2025-04-27",
      "last_synced_at": "2026-06-26T11:22:01.605Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06947850"
    },
    {
      "nct_id": "NCT04035668",
      "title": "A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sjögren Syndrome"
      ],
      "interventions": [
        {
          "name": "Remibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 73,
      "start_date": "2019-07-12",
      "completion_date": "2021-11-23",
      "has_results": true,
      "last_update_posted_date": "2023-01-30",
      "last_synced_at": "2026-06-26T11:22:01.605Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04035668"
    },
    {
      "nct_id": "NCT07264517",
      "title": "Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "GRF312 5%",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Instituto Grifols, S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 103,
      "start_date": "2025-11-03",
      "completion_date": "2026-05-20",
      "has_results": false,
      "last_update_posted_date": "2026-06-16",
      "last_synced_at": "2026-06-26T11:22:01.605Z",
      "location_count": 10,
      "location_summary": "Glendale, California • Grove, California • Newport Beach, California + 7 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Grove",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Morrow",
          "state": "Georgia"
        },
        {
          "city": "Carmel",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07264517"
    },
    {
      "nct_id": "NCT07413172",
      "title": "Autologous Serum Tears With Hyaluronate vs Balanced Salt Solution for Moderate-to-Severe Dry Eye",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye",
        "Eye Diseases",
        "Eyes Dry Chronic"
      ],
      "interventions": [
        {
          "name": "Autologous Serum Tears (50% Autologous Serum Tears + 0.2% Sodium Hyaluronate)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biological - Autologous Serum Tears (50% Autologous Serum Tears + Balanced Saline Solution (BSS)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard of Care (SOC) Treatment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2026-07",
      "completion_date": "2028-07",
      "has_results": false,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-06-26T11:22:01.605Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07413172"
    },
    {
      "nct_id": "NCT06370039",
      "title": "Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "INV-102",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Invirsa, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 109,
      "start_date": "2024-03-27",
      "completion_date": "2024-07-03",
      "has_results": false,
      "last_update_posted_date": "2025-07-02",
      "last_synced_at": "2026-06-26T11:22:01.605Z",
      "location_count": 1,
      "location_summary": "Rush, New York",
      "locations": [
        {
          "city": "Rush",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06370039"
    },
    {
      "nct_id": "NCT06245408",
      "title": "A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Sjögren's Syndrome (SS)"
      ],
      "interventions": [
        {
          "name": "Dazodalibep",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 434,
      "start_date": "2024-04-08",
      "completion_date": "2026-12-17",
      "has_results": false,
      "last_update_posted_date": "2026-01-08",
      "last_synced_at": "2026-06-26T11:22:01.605Z",
      "location_count": 41,
      "location_summary": "Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 37 more",
      "locations": [
        {
          "city": "Avondale",
          "state": "Arizona"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06245408"
    }
  ]
}